24 SCHOOL ST., 2ND FLOOR, BOSTON, MA
CEO to Present at Precision Medicine Forum Europe 2026 in Stockholm
Advances Stenoparib Toward Pivotal Development with Phase 3 Manufacturing Campaign
Annual Report to Security Holders
The Stenoparib DRP® Test Has Received a Notice of Allowance from the US Patent and Trademark Office
Presents Two AACR 2026 Posters Highlighting Stenoparib’s Potential in Colorectal Cancer as well as New Predictive Data Linking DRP® and Overall Survival in Ovarian Cancer
Reports Full Year 2025 Financial Results and Corporate Progress
Closes $20 Million Financing to Accelerate the Advance of Stenoparib Toward FDA Approval and Commercialization
Allarity Therapeutics Enters $10.93M Note Purchase Agreement with Lender
Q3
Q2
Notice of Late Filing for Quarterly Report
Q1
FY 2024
Prospectus filed pursuant to Rule 424(b)(3)
Amended Registration Statement for Securities Offered under a Shelf Registration
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(5)
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Amended Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload
Definitive Revised Proxy Statement